{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:35:12Z","timestamp":1793262912956,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jiac.2026.103083","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:33:03Z","timestamp":1789666383000},"page":"103083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of hepatitis B virus coinfection in people with human immunodeficiency virus: Current guidelines, challenges, and future perspectives in Japan"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5415-0854","authenticated-orcid":false,"given":"Ei","family":"Kinai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jiac.2026.103083_bib4","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jvh.13217","article-title":"Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis","volume":"27","author":"Platt","year":"2020","journal-title":"J Viral Hepat"},{"issue":"10","key":"10.1016\/j.jiac.2026.103083_bib5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/jvh.12555","article-title":"HBV\/HIV coinfection is associated with poorer outcomes in hospitalized patients with HBV or HIV","volume":"23","author":"Rajbhandari","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jiac.2026.103083_bib6","series-title":"Anti-HIV treatment guidelines","year":"2026"},{"key":"10.1016\/j.jiac.2026.103083_bib8","series-title":"EACS guidelines 2025, v13.0","year":"2025"},{"issue":"7","key":"10.1016\/j.jiac.2026.103083_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf368","article-title":"Optimizing the use of cabotegravir plus rilpivirine long-acting therapy in HIV care: evidence, implementation, and unanswered questions","volume":"12","author":"Geretti","year":"2025","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.jiac.2026.103083_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2024.116666","article-title":"Advancing hepatitis B elimination: a systematic review of global immunization progress and future directions","volume":"111","author":"Madihi","year":"2025","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"12","key":"10.1016\/j.jiac.2026.103083_bib11","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1473-3099(16)30463-7","article-title":"Introduction of a hepatitis B vaccine into the national routine immunisation programme of Japan","volume":"16","author":"Ujiie","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.jiac.2026.103083_bib12","first-page":"1534","article-title":"Strategy vaccination against hepatitis B in China","volume":"11","author":"Liao","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"9","key":"10.1016\/j.jiac.2026.103083_bib13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2016.04.030","article-title":"Continuing decrease in hepatitis B virus infection 30 years after initiation of infant vaccination program in Taiwan","volume":"14","author":"Ni","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jiac.2026.103083_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3350\/cmh.2021.0277","article-title":"History and future of hepatitis B virus control in South Korea","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jiac.2026.103083_bib16","article-title":"Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan: a simulation study","volume":"22","author":"Tanaka","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"10003","key":"10.1016\/j.jiac.2026.103083_bib17","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jiac.2026.103083_bib18","article-title":"Hepatitis B and C co-infection in HIV patients from the TREAT Asia HIV Observational Database: analysis of risk factors and survival","volume":"11","author":"Chen","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jiac.2026.103083_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12985-020-01404-z","article-title":"Hepatitis B and hepatitis C prevalence among people living with HIV\/AIDS in China: a systematic review and meta-analysis","volume":"17","author":"Yu","year":"2020","journal-title":"Virol J"},{"issue":"2","key":"10.1016\/j.jiac.2026.103083_bib20","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jmii.2019.10.005","article-title":"Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization program in Taiwan","volume":"54","author":"Lin","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"10.1016\/j.jiac.2026.103083_bib21","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1872-034X.2007.00263.x","article-title":"Prevalence of hepatitis B virus infection in Japanese patients with HIV","volume":"38","author":"Koike","year":"2008","journal-title":"Hepatol Res"},{"issue":"4","key":"10.1016\/j.jiac.2026.103083_bib22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3947\/ic.2017.49.4.268","article-title":"Human immunodeficiency virus (HIV) and hepatitis virus coinfection among HIV-infected Korean patients: the Korea HIV\/AIDS Cohort study","volume":"49","author":"Kim","year":"2017","journal-title":"Infect Chemother"},{"key":"10.1016\/j.jiac.2026.103083_bib23","series-title":"Prevalence of chronic hepatitis B in Hong Kong","year":"2024"},{"issue":"6","key":"10.1016\/j.jiac.2026.103083_bib24","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10156-012-0433-4","article-title":"Chronic hepatitis B in patients coinfected with human immunodeficiency virus in Japan: a retrospective multicenter analysis","volume":"18","author":"Yanagimoto","year":"2012","journal-title":"J Infect Chemother"},{"issue":"2","key":"10.1016\/j.jiac.2026.103083_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2024.11.007","article-title":"Current management and awareness of hepatitis coinfection in HIV care: a single-center retrospective study in Japan","volume":"31","author":"Konishi","year":"2025","journal-title":"J Infect Chemother"},{"issue":"6","key":"10.1016\/j.jiac.2026.103083_bib26","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1097\/HEP.0000000000000384","article-title":"Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men","volume":"77","author":"Mizushima","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jiac.2026.103083_bib29","series-title":"Hepatitis B treatment guidelines","year":"2022"},{"issue":"4","key":"10.1016\/j.jiac.2026.103083_bib30","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jiac.2026.103083_bib31","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jiac.2026.103083_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"11","key":"10.1016\/j.jiac.2026.103083_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0336924","article-title":"Serology change-based clinical interpretation of indeterminate serostatus post-hepatitis B virus infection in people living with HIV","volume":"20","author":"Kinai","year":"2025","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jiac.2026.103083_bib35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1086\/599610","article-title":"Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women","volume":"49","author":"French","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"9","key":"10.1016\/j.jiac.2026.103083_bib36","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/522173","article-title":"Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy","volume":"45","author":"Sheng","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jiac.2026.103083_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJM199907013410104","article-title":"Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease","volume":"341","author":"Cacciola","year":"1999","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jiac.2026.103083_bib37","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s40121-025-01192-5","article-title":"Advanced liver disease events in people with HIV and hepatitis B virus coinfection initiating antiretroviral therapy in the United States","volume":"14","author":"Chuo","year":"2025","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.jiac.2026.103083_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/QAD.0000000000004353","article-title":"Monitoring and risk of hepatitis B reactivation and hepatitis flare during tenofovir interruption among people with HIV and hepatitis B","volume":"40","author":"Dieterich","year":"2026","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.jiac.2026.103083_bib39","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3018(23)00151-0","volume":"10","author":"Avihingsanon","year":"2023","journal-title":"Lancet HIV"},{"issue":"7","key":"10.1016\/j.jiac.2026.103083_bib42","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/v14071504","article-title":"Occult hepatitis B virus infection: an update","volume":"14","author":"Saitta","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jiac.2026.103083_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107294","article-title":"Kinetics of hepatitis B virus replication in anti-HBc positive\/HBsAg-negative people with HIV switching to tenofovir sparing therapy","volume":"150","author":"Salpini","year":"2025","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.jiac.2026.103083_bib44","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/hiv.70231","article-title":"Hepatitis B reactivation in people living with HIV and isolated anti-HBc receiving tenofovir-sparing dual antiretroviral therapy","volume":"27","author":"Arcos-Rueda","year":"2026","journal-title":"HIV Med"},{"issue":"6","key":"10.1016\/j.jiac.2026.103083_bib45","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/cid\/ciag023","article-title":"Hepatitis B outcomes after switching to long-acting cabotegravir\/rilpivirine in people with HIV: reactivation, incident infection, and liver safety across diverse serological profiles","volume":"82","author":"Foncillas","year":"2026","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jiac.2026.103083_bib49","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/QAI.0000000000003239","article-title":"Brief report: hepatitis B infection or reactivation after switch to 2-drug antiretroviral therapy: a case series, literature review, and management discussion","volume":"94","author":"Vasishta","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.jiac.2026.103083_bib51","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1186\/s12879-024-09904-x","article-title":"Long-acting antiretroviral therapy effectiveness and patient satisfaction using patient questionnaires: data from a real-world setting","volume":"24","author":"Konishi","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"Suppl 9","key":"10.1016\/j.jiac.2026.103083_bib52","first-page":"70","article-title":"Simplification to dual (2D) antiretroviral therapy (ART) with lamivudine and dolutegravir in HIV-infected patients with solid organ transplantation (SOT): a preliminary single-center experience","volume":"20","author":"Castelli","year":"2019","journal-title":"HIV Med"},{"issue":"8","key":"10.1016\/j.jiac.2026.103083_bib48","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3201\/eid3008.240019","article-title":"Hepatitis B virus reactivation after switch to cabotegravir\/rilpivirine in patient with low hepatitis B surface antibody","volume":"30","author":"Adachi","year":"2024","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.jiac.2026.103083_bib53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jcv.2007.01.011","article-title":"Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy","volume":"39","author":"Schnepf","year":"2007","journal-title":"J Clin Virol"},{"issue":"9","key":"10.1016\/j.jiac.2026.103083_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa367","article-title":"Acute hepatitis B infection after a switch to long-acting cabotegravir and rilpivirine","volume":"7","author":"Pintado","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.jiac.2026.103083_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf754","article-title":"Hepatitis B surface antibody clearance after vaccination in people with HIV","volume":"13","author":"Ursenbach","year":"2026","journal-title":"Open Forum Infect Dis"},{"issue":"5","key":"10.1016\/j.jiac.2026.103083_bib47","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/cid\/ciab1020","article-title":"Evolution of hepatitis B virus (HBV) serologic markers among antiretroviral-naive young people living with human immunodeficiency virus who had undergone neonatal HBV vaccination and initiated antiretroviral therapy","volume":"75","author":"Huang","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.jiac.2026.103083_bib55","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7326\/ANNALS-25-01939","article-title":"Once-weekly oral islatravir plus lenacapavir versus daily oral bictegravir, emtricitabine, and tenofovir alafenamide in persons with HIV-1: a phase 2 randomized study","volume":"179","author":"Colson","year":"2026","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.jiac.2026.103083_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2025.101283","article-title":"Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: Week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study","volume":"7","author":"Ogbuagu","year":"2026","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jiac.2026.103083_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.745541","article-title":"Immune response to hepatitis B virus vaccine among people living with HIV: a meta-analysis","volume":"12","author":"Tian","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.jiac.2026.103083_bib58","first-page":"30","article-title":"Study on the status of viral hepatitis infection in HIV infection and the effectiveness of hepatitis A and B vaccines (article in Japanese)","volume":"9","author":"Nishida","year":"2007","journal-title":"J AIDS Res"},{"issue":"11","key":"10.1016\/j.jiac.2026.103083_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187661","article-title":"Durability of immunity by hepatitis B vaccine in Japanese health care workers depends on primary response titers and durations","volume":"12","author":"Yoshioka","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jiac.2026.103083_bib60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.vaccine.2018.11.019","article-title":"Acquisition rate of antibody to hepatitis B surface antigen among medical and dental students in Japan after three-dose hepatitis B vaccination","volume":"37","author":"Nagashima","year":"2019","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jiac.2026.103083_bib61","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamainternmed.2016.0741","article-title":"Long-term immune response to hepatitis B virus vaccination regimens in adults with human immunodeficiency virus 1: secondary analysis of a randomized clinical trial","volume":"176","author":"Launay","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"11","key":"10.1016\/j.jiac.2026.103083_bib62","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1473-3099(15)00220-0","article-title":"Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial","volume":"15","author":"Rey","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.jiac.2026.103083_bib63","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1473-3099(12)70243-8","article-title":"Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1","volume":"12","author":"Whitaker","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.jiac.2026.103083_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080409","article-title":"Comparison of immunogenicity and safety of four doses and four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: a randomized, controlled trial","volume":"8","author":"Chaiklang","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jiac.2026.103083_bib65","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1468-1293.2007.00473.x","article-title":"Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine","volume":"8","author":"Shafran","year":"2007","journal-title":"HIV Med"},{"issue":"4","key":"10.1016\/j.jiac.2026.103083_bib66","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.2024.24490","article-title":"HepB-CpG vs HepB-Alum vaccine in people with HIV and prior vaccine nonresponse: the BEe-HIVe randomized clinical trial","volume":"333","author":"Marks","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jiac.2026.103083_bib68","year":"2026"},{"issue":"12","key":"10.1016\/j.jiac.2026.103083_bib69","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/cit145","article-title":"Prophylactic effect of antiretroviral therapy on hepatitis B virus infection","volume":"56","author":"Gatanaga","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jiac.2026.103083_bib70","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/QAD.0000000000000180","article-title":"Protective effect of hepatitis B virus-active antiretroviral therapy against primary hepatitis B virus infection","volume":"28","author":"Heuft","year":"2014","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.jiac.2026.103083_bib71","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/COH.0000000000001016","article-title":"Use of dual ART in individuals with different HBV serological patterns","volume":"21","author":"Swaine","year":"2026","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"10.1016\/j.jiac.2026.103083_bib72","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jhep.2022.09.027","article-title":"Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression","volume":"78","author":"Gane","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jiac.2026.103083_bib73","article-title":"Design and analysis considerations for early phase clinical trials in hepatitis B (HBV) cure research: the ACTG A5394 study in persons with both HIV and HBV","volume":"9","author":"Kang","year":"2023","journal-title":"J Virus Erad"},{"issue":"24","key":"10.1016\/j.jiac.2026.103083_bib75","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2515131","article-title":"Phase 3 results of bepirovirsen treatment for chronic hepatitis B virus infection","volume":"394","author":"Hou","year":"2026","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jiac.2026.103083_bib77","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an immunomodulator in chronic hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:11:48Z","timestamp":1793261508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26001819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1341321X26001819"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103083","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of hepatitis B virus coinfection in people with human immunodeficiency virus: Current guidelines, challenges, and future perspectives in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103083"}}